Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?

• Published in: Pharmacogenomics 2015-04, Vol.16 (6), p.573-582
• Main Authors: Rieck, Mariana, Schumacher-Schuh, Artur F, Callegari-Jacques, Sidia M, Altmann, Vivian, Schneider Medeiros, Márcio, Rieder, Carlos Rm, Hutz, Mara H
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Complications and side effects; Drug metabolism; Drug therapy; Dyskinesia, Drug-Induced - diagnosis; Dyskinesia, Drug-Induced - genetics; Female; Genetic aspects; Genetic Association Studies - methods; Genetic polymorphisms; Health aspects; Humans; L-dopa; Levodopa - adverse effects; Male; Middle Aged; Parkinson disease; Parkinson Disease - diagnosis; Parkinson Disease - drug therapy; Parkinson Disease - genetics; Polymorphism, Single Nucleotide - genetics; Receptor, Adenosine A2A - physiology
• ISSN: 1462-2416; 1744-8042
• DOI: 10.2217/pgs.15.23

Levodopa is first line treatment of Parkinson's disease (PD). However, its use is associated with the presence of motor fluctuations and dyskinesias. In recent years, adenosine A2A receptor (A2AR) is rising as a therapeutic target for PD. The aim of the present study was to investigate whether ADORA2A is associated with levodopa adverse effects. Two hundred and eight PD patients on levodopa therapy were investigated. rs2298383 and rs3761422 at the ADORA2A gene were genotyped by allelic discrimination assays. A trend for association was observed for both polymorphism and diplotypes with dyskinesia. The present results should be considered as positive preliminary evidence. Further studies are needed to determine the association between ADORA2A and dyskinesia. Original submitted 3 December 2014; Revision submitted 13 February 2015.